TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...

Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...

However, there is currently no consensus on the standard of care for this population. Durvalumab, an immune checkpoint ...

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report.

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer ...

Discover the trials that have shown why Predictive biomarkers are expected to play a pivotal role in further enhancing ...

This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients ...

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and ...

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...

AstraZeneca Pharma India has gained approval from India's drug regulator to import cancer treatment drug Lynparza for sale. The tablets are for use in combination therapy for patients with specific ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...